News | oneAMYLOIDOSISvoice

News

ATTRwt Research Study: Days alive and out of hospital in patients with ATTRwt

Gene Editing Offers Hope for Progressive Cardiomyopathy Due to Amyloidosis

New Era of Medicine: Researchers Publish First Positive Clinical Data for In Vivo Genome Editing in Humans

Gene Editing Therapy Paves Way for Revolution in Treatment of Genetic Disorders

CRISPR Injected Into the Blood Treats a Genetic Disease for First Time

Landmark CRISPR Trial Shows Promise Against Deadly Disease

Untangling Amyloidosis Symposium 2021

ISA Virtual Workshop on Diagnosis of Amyloidosis

XIX ISA Symposium on Amyloidosis 2024

Alnylam Reports Positive Topline 18-Month Results From HELIOS-A Phase 3 Study of Vutrisiran in Patients With hATTR Amyloidosis With Polyneuropathy

ISA Virtual Workshop on Gaps in Diagnosis and Management of AL Amyloidosis

Subscribe to

Newsletter

Expert and Community Perspectives on Attruby®

In this special session, Dr. Barry Trachtenberg and members of the ATTR amyloidosis community came together to share medical insights and lived experiences related to Attruby™ (acoramidis). This expert-led discussion explores the clinical data, the patient perspective, and what lies ahead for those considering or currently taking Attruby.